Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal.

CLEOPATRA was a pivotal phase III study where researchers evaluated the safety and efficacy of pertuzumab, trastuzumb and chemotherapy in 808 patients with previously untreated HER2-positive metastatic breast cancer. HER2-positive metastatic breast cancer has historically been one of the most aggressive forms of the disease.

READ FULL ARTICLE Curated publisher From News Medical